Dobutamine

Dobutamine is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors) . Dobutamine is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine can increase cardiac output and correct hypoperfusion[1][2][3][4].

Product Specifications

CAS Number

[34368-04-2]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/dobutamine.html

Concentration

10mM

Purity

98.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=C(CCNC(C)CCC2=CC=C(O)C=C2)C=C1O

Molecular Formula

C18H23NO3

Molecular Weight

301.38

Precautions

H302, H312, H332

References & Citations

[1]Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36 (1) :185-96.|[2]Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris) . 1991 Jun;40 (6) :397-402.|[3]Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37 (3) :669-77.|[4]Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156 (2 Pt 1) :438-44.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

α adrenergic receptor; β adrenergic receptor

Citation 01

Biochem Pharmacol. 2025 Nov 29:244:117576.|Comput Struct Biotechnol J. 2023 Jul 7:21:3490-3502.|Environ Toxicol. 2024 Mar;39 (3) :1682-1699.|Anal Chem. 2025 Jul 15;97 (27) :14220-14229.|Front Cell Dev Biol. 2022 Apr 20;10:889656.